NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Treace Medical Concepts, Inc. (TMCI) Stock Analysis

Treace Medical Concepts, Inc. (TMCI) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TMCI

$4.14

+$0.07 (+1.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TMCI with… →

TMCI Key Statistics

As of Oct 21, 2026
Trading
Open
$4.05
Previous Close
$4.07
Day's Range
3.85–4.14
52-Week Range
1.17–7.08
Volume
196.53K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.49
Valuation
Market Cap
$269.24M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.92
Financials (FY)
Revenue (FY)
$212.69M+1.59%
Net Income (FY)
−$59.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−28.99%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.03M
1-Year Return
−40.43%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
295.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TMCI closed at $4.14, −40.43% over 1 year.

Treace Medical Concepts, Inc. (TMCI) has a market capitalization of $269.24M.

In fiscal 2025, TMCI reported revenue of $212.69M.

TMCI Stock Return by Calendar Year

Treace Medical Concepts, Inc. (TMCI) return since Apr 2021: what $10,000 became

1 year
$10,000 $5,957
−40.43%
5 years
$10,000 $2,075
−79.25%
Since Apr 2021
$10,000 $1,622
−83.78%

If you had invested $10,000 in Treace Medical Concepts, Inc. (TMCI) at the close on April 23, 2021, the earliest close on record here, it would have been worth $1,622 at the close on October 21, 2026: −83.78% in total, −28.18% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+68.98%
2025−67.07%
2024−41.65%
2023−44.54%
2022+23.34%
2021 (partial year)−26.99%

As of October 21, 2026.

TMCI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$212.69M−$59.00M−27.7%
2024$209.36M−$55.74M−26.6%
2023$187.12M−$49.53M−26.5%
2022$141.84M−$42.82M−30.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$212.69M$169.75M−$54.15M−$59.00M−27.7%
2024$209.36M$168.26M−$55.69M−$55.74M−26.6%
2023$187.12M$151.94M−$51.43M−$49.53M−26.5%
2022$141.84M$116.31M−$34.84M−$42.82M−30.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TMCI Valuation vs Medical Devices Median

Median of 145 stocks
MetricTMCIMedical Devices medianvs median
P/S ratio1.312.5348% below
Profit margin−28.99%−14.78%14.2 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Treace Medical Concepts, Inc. (TMCI) at $269.24M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 450 employees.

Over the past 52 weeks the price has ranged from $1.17 to $7.08. TMCI last closed at $4.14 on October 21, 2026. That is +$0.07 (+1.72%) against the previous close. The latest close sits 253.85% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $212.69M. Against the prior fiscal year total of $209.36M, that is a change of +1.59%. The same year closed with a net loss of $59.00M. The reported profit margin is −28.99%. That is 14.2 percentage points below the Medical Devices median of −14.78%. Trailing earnings per share are −0.92.

Across the 4 fiscal years on file, revenue moves from $141.84M in 2022 to $212.69M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.31. On price-to-sales that is 48.16% below the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.49. Annualized volatility over the trailing 5 years is 76.18%. The trailing one-year total return is −40.43%. Measured over 5 years, that is −26.99% a year compounded.

Growth & Income

The record shows no dividend for TMCI.

Across the complete calendar years on file, 2022 returned +23.34% and 2025 returned −67.07%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is +68.98% year to date.

Peer Comparison

Treace Medical Concepts, Inc. (TMCI) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Treace Medical Concepts, Inc. TMCI $269.24M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Treace Medical Concepts, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Visit website →